Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesGastroenterologyBCBS Vermont IB-STIM Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of VermontPolicy 10.99.VT85

    Percutaneous Electrical Nerve Field Stimulation for Functional Abdominal Pain Disorders

    Customize your policy alerts

    Sign up for bcbsvermont Policy 10.99.VT85 alerts

    Get alerted when Policy 10.99.VT85 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for IB-STIM percutaneous electrical nerve field stimulation in children and adolescents with ROME IV-defined functional gastrointestinal disorders. It establishes medical-necessity criteria, investigational nonqualifying uses, coding instructions, and related equipment-replacement rules for eligible Blue Cross Blue Shield of Vermont members.

    Policy Summary
    PayerBlue Cross Blue Shield of Vermont
    PolicyPercutaneous Electrical Nerve Field Stimulation for Functional Abdominal Pain Disorders
    Policy CodePolicy 10.99.VT85
    Change TypeCoding update
    Effective DateDec 1, 202635d
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2027
    Key ActionObtain prior approval for CPT 64567 and submit documentation demonstrating that all policy criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Effective January 1, 2026, CPT code 0720T was deleted from the prior-approval coding table.

    Effective January 1, 2026, CPT code 64567 was added to the prior-approval coding table.

    The August 2026 policy review reported no change to the policy statement and updated references.

    11–21Eligible age range
    9 monthsMinimum symptom duration
    3Medication categories required
    64567Procedure code requiring prior approval
    41 weeksMaximum treatment duration

    Medical Necessity and Nonqualifying Uses

    Medically Necessary IB-STIM

    The IB-STIM® device may be considered medically necessary in children and adolescents when ALL of the following criteria are met:

    ALL of the following

    • The patient is 11–21 years of age.
    • The patient has a ROME IV-defined functional gastrointestinal disorder, including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine.
    • Organic gastrointestinal disease has been ruled out.
    • The problem has been present for at least 9 months.>= 9 months
    • The patient has tried and failed medications in all three categories: acid suppression (H2 blockers or PPIs); antispasmodics or motility medications (hyoscyamine, dicyclomine, erythromycin, linaclotide, or prucalopride); and neuromodulators (amitriptyline, nortriptyline, gabapentin, Periactin, or aprepitant), in addition to diet modification.

    Investigational Uses

    All other uses of the IB-STIM® device not meeting the medical-necessity criteria above are considered investigational.

    Investigational uses include any of the following

    • Use in patients who are not 11–21 years of age.
    • Use for a condition that is not a ROME IV-defined functional gastrointestinal disorder, including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine.
    • Use when organic gastrointestinal disease has not been ruled out.
    • Use when the problem has been present for less than 9 months.
    • Use when the patient has not tried and failed medications in all three required categories, in addition to diet modification.
    • Any other use of the IB-STIM® device that does not meet all medical-necessity criteria.

    Uses of the IB-STIM® device that do not meet all of the medical-necessity criteria are considered investigational.

    Replacement of lost, stolen, or destroyed durable medical equipment, prosthetics, or orthotics is not covered if the medical-necessity criteria above have not been met and the request is for more than one lost, stolen, or destroyed durable medical equipment, prosthetic, or orthotic per Plan Year.

    Prior-Approval Coding

    Prior Approval RequiredCPT
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Approval Required

    Prior approval is required for CPT 64567, subject to applicable benefit terms and limitations. The code describes percutaneous electrical nerve field stimulation of the cranial nerves without implantation.

    • CPT 64567 — Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
    • Policy instruction: Prior Approval Required.
    Step Therapy

    Required Treatment History

    For IB-STIM® to be considered medically necessary, the patient must have tried and failed medication therapy in all three required categories, in addition to diet modification.

    • Acid suppression: H2 blockers or PPIs.
    • Antispasmodic or motility medications: hyoscyamine, dicyclomine, erythromycin, linaclotide, or prucalopride.
    • Neuromodulators: amitriptyline, nortriptyline, gabapentin, Periactin, or aprepitant.
    • Diet modification must also have been tried and failed.
    Documentation Required

    Medical-Necessity Documentation

    Submit documentation supporting that the patient meets the medical-necessity criteria, including eligibility, the qualifying diagnosis, exclusion of organic gastrointestinal disease, duration of symptoms, and prior treatment history.

    • Document age 11–21 years.
    • Document the ROME IV-defined functional gastrointestinal disorder diagnosis.
    • Document that organic GI disease has been ruled out.
    • Document that the problem has been present for at least 9 months.
    • Document failed medications in all three categories and failed diet modification.
    Documentation Required

    Document Stolen Equipment

    For a replacement request involving stolen durable medical equipment, submit supporting documentation with the request, such as a police report.

    • Replacement is subject to the applicable replacement criteria, including warranty status and risk of significant negative health consequences if the equipment is absent.
    Denial Risk

    Nonqualifying IB-STIM® Use

    Uses of the IB-STIM® device that do not meet all of the medical-necessity criteria are considered investigational.

    • Nonqualifying uses are not covered as medically necessary under this policy.
    Prior Authorization

    Complete Authorization and Verify Benefits

    Submit complete authorization information before requesting a determination. Incomplete requests may be delayed while missing information is obtained, and benefits must be verified before providing the service because coverage varies by contract and member group.

    • Confirm that the authorization request addresses the policy guidelines and includes all required clinical documentation.
    • Verify member benefits and any applicable exclusions with the health plan or customer service department.
    • NEHP/ABNE, FEP, ASO, and other group or individual contracts may have different benefits; contract language takes precedence when it conflicts with the policy.
    Denial Risk

    DME Replacement Limits

    Replacement of lost, stolen, or destroyed durable medical equipment is excluded when the replacement criteria are not met or when more than one item has already been replaced during the plan year.

    • No more than one lost, stolen, or destroyed item may be replaced per Plan Year.
    • The item must not be covered by an alternative entity, must still be under warranty, and its absence must pose a risk of death, disability, hospital admission, or another significant negative health consequence.

    Therapy Overview

    Percutaneous electrical nerve field stimulation delivers electrical impulses through the external ear to cranial nerve bundles and brain areas involved in pain processing. IB-STIM is intended for pediatric patients with functional abdominal pain associated with functional gastrointestinal disorders, including irritable bowel syndrome, and is typically administered in an office setting. The policy cites randomized, double-blind, sham-controlled trials reporting reductions in abdominal pain and improvements in overall symptoms among adolescents.

    Key Terms

    IB-STIM
    Device typePercutaneous electrical nerve field stimulator (PENFS) system
    Intended populationPatients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS)
    Nerve targetsBranches of cranial nerves V, VII, IX, and X, and the occipital nerves identified by transillumination
    Intended useAid in the reduction of pain when combined with other therapies for IBS
    Treatment duration120 hours per week for up to 41 consecutive weeks
    ROME IV-Defined Functional Gastrointestinal Disorders
    Functional abdominal painA ROME IV-defined functional gastrointestinal disorder
    Functional abdominal pain syndromeA ROME IV-defined functional gastrointestinal disorder
    Irritable bowel syndromeA ROME IV-defined functional gastrointestinal disorder
    Functional dyspepsiaA ROME IV-defined functional gastrointestinal disorder
    Abdominal migraineA ROME IV-defined functional gastrointestinal disorder
    Policy Summary
    PayerBlue Cross Blue Shield of Vermont
    PolicyPercutaneous Electrical Nerve Field Stimulation for Functional Abdominal Pain Disorders
    Policy CodePolicy 10.99.VT85
    Change TypeCoding update
    Effective DateDec 1, 202635d
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2027
    Key ActionObtain prior approval for CPT 64567 and submit documentation demonstrating that all policy criteria are met.
    SourceLink
    On This Page
    Medical Necessity and Nonqualifying UsesPrior-Approval CodingAuthorization and Documentation RequirementsTherapy OverviewKey Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.